Cervical Cancer Staging: How FIGO Classification Guides Treatment

When a woman is diagnosed with cervical cancer, one of the first questions her medical team works to answer is not simply whether she has cancer, but how far it has spread. That question — the question of stage — is arguably more important than any other in shaping what happens next.

Two women with the same diagnosis can have entirely different treatment paths, different prognoses, and different possibilities for preserving fertility, depending on the stage of their disease. Staging is not a bureaucratic formality. It is the foundation on which every subsequent decision rests.

Cervical cancer is staged using a classification system known as FIGO, developed by the International Federation of Gynecology and Obstetrics. It is the most widely used staging system for cervical cancer worldwide, and understanding how it works is essential for any woman navigating a diagnosis — or for anyone trying to make sense of the language her medical team is using.

For a complete overview of cervical cancer, see Cervical Cancer: Causes, Symptoms, Screening, Stages, and Treatment (Complete Guide).

⸻

What Staging Actually Means

Staging is the medical process of determining how much of the body is affected by a cancer. For cervical cancer, this involves answering several specific questions: Is the tumor confined to the cervix itself? Has it extended into nearby tissues? Has it reached the lymph nodes? Are there signs of spread to distant organs?

The answers to these questions are combined into a single classification — a stage — that describes the extent of disease in standardized terms. This allows physicians around the world to communicate about a patient's condition using a shared vocabulary. A patient staged as 1B1 in one country means exactly the same thing in another.

Staging matters for three main reasons. It determines prognosis, meaning the likely outcome based on how the disease typically behaves at that stage. It guides treatment, because different stages call for different therapeutic approaches. And it allows meaningful comparison across clinical trials, since researchers can study how specific treatments perform within defined stages of disease.

⸻

The FIGO Staging System

The FIGO system divides cervical cancer into four main stages, each representing a broader extent of disease. Within each main stage, subdivisions describe more specific patterns of spread — the exact size of the tumor, how deep it has invaded, which structures beyond the cervix may be involved.

The most recent version of FIGO staging, updated in 2018 and widely adopted in clinical practice, incorporates imaging findings and pathology results into the staging process. Earlier versions relied almost entirely on clinical examination. The modern system is more accurate because it reflects what can actually be seen on MRI and other advanced imaging studies.

⸻

Stage 1: Cancer Confined to the Cervix

Stage 1 describes cervical cancer that is limited to the cervix itself. It has not spread to surrounding tissues, to the vagina, or to any distant site. This is the earliest invasive stage of the disease, and it is the stage at which treatment outcomes are best.

Within Stage 1, the classification becomes more detailed depending on the size and depth of the tumor.

Stage 1A describes microscopic cancer — disease that cannot be seen with the naked eye and is identified only through pathological examination. Stage 1A1 indicates invasion of less than 3 millimeters in depth. Stage 1A2 describes invasion between 3 and 5 millimeters.

Stage 1B describes visible tumors confined to the cervix. Stage 1B1 includes tumors up to 2 centimeters in largest dimension. Stage 1B2 includes tumors between 2 and 4 centimeters. Stage 1B3 describes tumors larger than 4 centimeters but still confined to the cervix.

The significance of these subdivisions becomes clear in treatment planning. Stage 1A1, for example, may be treated with a relatively conservative procedure such as conization in selected patients. Stage 1B1, in a younger woman who wishes to preserve fertility, may be a candidate for fertility-sparing surgery rather than full hysterectomy. Stage 1B3, by contrast, usually requires more extensive treatment.

For a full explanation of fertility-sparing options at early stages, see Fertility-Sparing Surgery for Cervical Cancer: What to Know.

⸻

Stage 2: Local Extension Beyond the Cervix

Stage 2 describes cervical cancer that has spread beyond the cervix but remains confined to nearby structures. It has not reached the pelvic wall and has not spread to the lower third of the vagina, to the lymph nodes, or to distant sites.

Stage 2A indicates tumor extension into the upper two-thirds of the vagina without involvement of the tissues surrounding the uterus. Stage 2A1 describes smaller tumors in this category, while Stage 2A2 describes larger ones.

Stage 2B describes tumor extension into the parametrium — the connective tissue that surrounds the uterus and extends toward the pelvic sidewall. Involvement of the parametrium is clinically important because it often determines whether surgery is appropriate as a first treatment or whether combined chemoradiation is preferred instead.

At Stage 2, fertility-sparing options generally become more limited, and treatment increasingly involves multimodal approaches combining surgery, radiation, and chemotherapy.

⸻

Stage 3: Locally Advanced Disease

Stage 3 describes cervical cancer that has spread more extensively within the pelvis. The disease has either reached the pelvic sidewall, extended into the lower third of the vagina, caused obstruction of the urinary system, or involved regional lymph nodes.

Stage 3A describes tumors that extend to the lower third of the vagina but do not reach the pelvic sidewall.

Stage 3B describes tumors that extend to the pelvic sidewall or that cause hydronephrosis — a backup of urine in one or both kidneys due to ureteral obstruction. This finding often reflects compression of the ureter by tumor tissue and is clinically significant both as a staging criterion and as a factor in overall kidney function.

Stage 3C describes involvement of lymph nodes. Stage 3C1 indicates pelvic lymph node involvement, while Stage 3C2 indicates involvement of the para-aortic lymph nodes — lymph nodes located along the major artery in the abdomen. This distinction matters because para-aortic involvement indicates a wider pattern of spread and influences both the design of radiation fields and the overall treatment approach.

Treatment at Stage 3 is typically based on concurrent chemoradiation — the simultaneous use of radiation therapy and chemotherapy. This combined approach has been shown to produce significantly better outcomes than either treatment alone.

⸻

Stage 4: Distant or Extensive Spread

Stage 4 describes the most advanced disease. The cancer has either invaded adjacent organs such as the bladder or rectum, or it has spread to distant sites in the body.

Stage 4A describes tumor invasion of nearby organs. This typically means the bladder or rectum, though involvement of other pelvic structures can also qualify. Diagnosis at this stage often requires imaging and, in some cases, direct visualization of the affected organs through cystoscopy or proctoscopy.

Stage 4B describes cervical cancer that has spread to distant sites — the lungs, liver, bones, or lymph nodes outside the pelvic region. At this stage, treatment shifts toward systemic therapies such as chemotherapy, targeted therapy, and immunotherapy, often with the goal of controlling the disease and maintaining quality of life rather than achieving cure.

Recent advances in immunotherapy, particularly with checkpoint inhibitors, have meaningfully improved outcomes for some women with Stage 4B disease — a significant change from a decade ago, when options at this stage were much more limited.

For a detailed overview of treatment approaches across different stages, see Treatment Options for Cervical Cancer: Surgery, Radiation, and Chemotherapy.

⸻

How Stage Is Actually Determined

Modern FIGO staging relies on a combination of clinical examination, imaging, and pathology. Each contributes specific information that together produces an accurate picture of the extent of disease.

Clinical Examination

The pelvic examination remains an essential starting point. It allows the gynecologic oncologist to assess the size and appearance of the tumor, to determine whether the cancer has extended into the vagina, and to feel for signs of involvement of the pelvic sidewall or surrounding tissues.

Imaging

Imaging has become increasingly central to staging since the 2018 revisions to FIGO. Two studies are particularly important:

• MRI of the pelvis is the single best imaging tool for assessing local tumor extension. It provides detailed visualization of the cervix, the surrounding tissues, the vaginal walls, and the involvement of the parametrium. The accuracy of MRI in measuring tumor size and detecting local spread is a major reason the staging system now formally incorporates imaging findings.
• PET-CT evaluates the body more broadly. It identifies metabolically active disease throughout the abdomen, chest, and pelvis — particularly useful for detecting lymph node involvement and distant metastases. Many centers now consider PET-CT essential for all patients with anything beyond microscopic disease.
• Additional imaging, such as CT of the chest, is sometimes used for specific questions or when PET-CT is not available.

Pathology

Pathological examination of tissue obtained through biopsy or surgery provides the final layer of staging information. Pathology identifies the specific type of cervical cancer — most commonly squamous cell carcinoma or adenocarcinoma — and characterizes features such as depth of invasion, involvement of lymphatic and vascular spaces, and whether cancer has reached the surgical margins of excised tissue.

When surgery is performed, pathology examination of the removed tissue often refines the initial clinical stage. A patient whose imaging suggested Stage 1B1 disease, for example, may be reclassified at surgery if unexpected findings are identified.

⸻

How Staging Guides Treatment Decisions

The treatment of cervical cancer varies dramatically by stage, which is why accurate staging is so important.

For early-stage disease — Stage 1A and much of Stage 1B — surgery is usually the primary treatment. In some cases, conservative surgical approaches are possible, including procedures that preserve fertility in younger women who wish to have children. Radiation and chemotherapy are not typically required at the earliest stages, provided pathology shows favorable features and surgical margins are clear.

For locally advanced disease — Stage 2B, Stage 3, and some presentations of Stage 1B3 — the standard approach has shifted away from surgery as a primary treatment. Concurrent chemoradiation has been shown to produce better outcomes in this population. Surgery may still play a role in selected cases, but it is no longer the default.

For metastatic or recurrent disease — Stage 4B, or cases where cervical cancer returns after initial treatment — systemic therapy becomes the backbone of care. Modern regimens often combine chemotherapy with targeted therapy or immunotherapy, with treatment intensity tailored to the patient's overall health and goals of care.

This is what staging does in practical terms. It takes a diagnosis of cervical cancer and transforms it into a specific treatment plan — one matched to the biology of the disease as it exists in a particular patient.

⸻

Staging and Prognosis

Staging is also closely tied to prognosis. Five-year survival rates vary substantially across stages, reflecting how much the disease has spread at the time of diagnosis.

Early-stage cervical cancer — disease confined to the cervix — is associated with excellent outcomes, with five-year survival rates typically exceeding 90 percent in Stage 1. Locally advanced disease has intermediate outcomes, with survival rates in the range of 40 to 70 percent depending on the specific substage and treatment response. Metastatic disease carries a more guarded prognosis, though recent advances in systemic therapy have meaningfully extended survival in this group.

These numbers should be understood as population averages rather than individual predictions. Many factors beyond stage influence outcome — including the specific cell type of the cancer, the response to initial treatment, overall health, and access to high-quality specialist care. But stage remains the single most powerful predictor of likely outcome, which is why accurate staging is so central to every treatment decision.

For guidance on when specialist care becomes essential, see When Should You See a Gynecologic Oncologist?.

⸻

Why Staging Matters for Patients

For a woman diagnosed with cervical cancer, staging can feel abstract — a set of numbers and letters that describe something happening inside her body. In practical terms, however, it is one of the most meaningful pieces of information she will receive.

Staging determines what treatments will be offered. It defines what is possible in terms of fertility preservation. It shapes what to expect during and after treatment. And it provides the framework within which her medical team will plan follow-up and monitoring in the years that follow.

Understanding the stage — and, more importantly, understanding what that stage means for her specific situation — is part of becoming an informed participant in her own care. It is also part of knowing the right questions to ask, both of the treating team and in any second opinion she may choose to pursue.

For the impact of diagnosis on younger women specifically, see Cervical Cancer in Young Women: Why Early Detection Matters.

⸻

Conclusion

FIGO staging is the language through which cervical cancer is understood, discussed, and treated. It translates an individual diagnosis into a standardized classification that drives everything from treatment selection to prognosis to long-term follow-up.

The four stages — confined to the cervix, extended locally, advanced within the pelvis, and spread beyond — each represent a different biological reality and call for different clinical responses. Within each stage, further subdivisions refine the picture further, guiding specific decisions about surgery, radiation, chemotherapy, and newer systemic therapies.

For women navigating a diagnosis, understanding staging is not optional. It is the foundation of every subsequent conversation — about what comes next, about what is possible, and about what outcomes to hope for. And for medicine as a whole, it is the reason cervical cancer treatment has become increasingly personalized, increasingly effective, and increasingly matched to the specific circumstances of each woman who faces the disease.

⸻

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individuals should consult a qualified healthcare provider for any medical concerns or decisions regarding diagnosis or treatment.